Wellnex Life (ASX:WNX) received market authorization from Australia's Therapeutic Goods Administration for its new liquid paracetamol plus caffeine soft gel, the company said in a Tuesday Australian bourse filing.
The product will provide opportunities to use it in the company's own brands as well as opportunities to license it to third parties, the filing added.
Company shares rose past 3% in recent Tuesday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.